Salvage Microsurgery After Failed Bevacizumab Treatment for NF2-Related Schwannomatosis Vestibular Schwannoma: A Multicentric Retrospective Study
Our findings suggest that a higher cumulative BEV dose (∼600 mg/kg) and a longer interval between BEV discontinuation and surgery (∼8 months) are associated with a modest but statistically significant increase in intraoperative bleeding risk. Based on these observations, a BEV-free window between 6 weeks and 6 months (depending on the clinical scenario) before tumor resection seems optimal, particularly for patients with high cumulative exposure.
Authors
- Andrew T. King (ORCID: https://orcid.org/0000-0002-6546-7248)
- Saba Raza-Knight
- John G. Golfinos (ORCID: https://orcid.org/0000-0003-4221-0180)
- Michel Kalamarides (ORCID: https://orcid.org/0000-0003-1037-9707)
- Danièle Bernardeschi (ORCID: https://orcid.org/0000-0002-5937-8847)
- Michael Bartellas (ORCID: https://orcid.org/0000-0003-2001-1404)
- John P. Marinelli (ORCID: https://orcid.org/0000-0003-2350-8942)
- J. Thomas Roland (ORCID: https://orcid.org/0000-0003-1181-4651)
- D. Gareth Evans (ORCID: https://orcid.org/0000-0002-8482-5784)
- Omar Pathmanaban (ORCID: https://orcid.org/0000-0002-5083-9416)
- Benoit Hudelist (ORCID: https://orcid.org/0000-0003-4543-8017)
- Michael J. Link
- Matthew L. Carlson
Institutions
- Mayo Clinic (US)
- Manchester Academic Health Science Centre (GB)
- Salford Royal NHS Foundation Trust (GB)
- University of Manchester (GB)
- Sorbonne Université (FR)
- NYU Langone Health (US)
- Pitié-Salpêtrière Hospital (FR)
- New York University (US)
Publication Details
- Journal
- Neurosurgery
- Published
- 2025-09-16
- DOI
- https://doi.org/10.1227/neu.0000000000003728
- Primary Topic
- Neurofibromatosis and Schwannoma Cases
- Type
- article
- Field-Weighted Citation Impact
- 0.00